Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

被引：0
|
作者：
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
机构：
[1] Massachusetts General Hospital and Harvard Medical School,Translational Discovery & Development
[2] Moffitt Cancer Center-McKinley Outpatient Clinic,undefined
[3] Mayo Clinic,undefined
[4] Sarah Cannon Research Institute/Tennessee Oncology,undefined
[5] Icahn School of Medicine at Mount Sinai,undefined
[6] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[7] Florida Cancer Specialists-South/Sarah Cannon Research Institute,undefined
[8] GSK,undefined
[9] Ludwig Center at Harvard,undefined
[10] EQRx,undefined
[11] Boston Pharmaceuticals,undefined
[12] Alkermes Incorporated,undefined
[13] Bicycle Therapeutics,undefined
来源：
Nature Cancer | 2022年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1138 / 1138
相关论文
共 50 条
  • [11] Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial
    Senkus, Elzbieta
    Delaloge, Suzette
    Domchek, Susan M.
    Conte, Pierfranco
    Im, Seock-Ah
    Xu, Binghe
    Armstrong, Anne
    Masuda, Norikazu
    Fielding, Anitra
    Robson, Mark
    Tung, Nadine
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 803 - 814
  • [12] Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
    Sun, Wanyi
    Wu, Yun
    Ma, Fei
    Fan, Jinhu
    Qiao, Youlin
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [13] Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
    Savill, Kristin M. Zimmerman
    Ivanova, Jasmina
    Asgarisabet, Parisa
    Falkenstein, Angelica
    Balanean, Alexandrina
    Niyazov, Alexander
    Ryan, Joanne C.
    Kish, Jonathan
    Gajra, Ajeet
    Mahtani, Reshma L.
    ONCOLOGIST, 2023, 28 (05): : 414 - 424
  • [14] Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Poggio, Francesca
    Bruzzone, Marco
    Ceppi, Marcello
    Conte, Benedetta
    Martel, Samuel
    Maurer, Christian
    Tagliamento, Marco
    Viglietti, Giulia
    Del Mastro, Lucia
    de Azambuja, Evandro
    Lambertini, Matteo
    ESMO OPEN, 2018, 3 (04)
  • [15] Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study
    Ales-Martinez, Jose E.
    Balmana, Judith
    Sanchez-Rovira, Pedro
    Bofill, Francisco Javier Salvador
    Garcia-Saenz, Jose Angel
    Pimentel, Isabel
    Murillo, Serafin Morales
    Fernandez, Adela
    Martinez, Ainhara Lahuerta
    Ferrer, Neus
    Zamora, Pilar
    Bermejo, Begona
    Diaz-Redondo, Tamara
    Lopez-Ceballos, Maria Helena
    Galan, Maria
    Malfettone, Andrea
    Calabuig, Laura
    Sampayo-Cordero, Miguel
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2023, 83 (05)
  • [16] Fertility preservation in BRCA-mutated breast cancer patients
    Lambertini, Matteo
    Del Mastro, Lucia
    BREAST CANCER MANAGEMENT, 2016, 5 (02) : 61 - 68
  • [17] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
    Judith Balmaña
    Peter A. Fasching
    Fergus J. Couch
    Suzette Delaloge
    Intidhar Labidi-Galy
    Joyce O’Shaughnessy
    Yeon Hee Park
    Andrea F. Eisen
    Benoit You
    Hughes Bourgeois
    Anthony Gonçalves
    Zoe Kemp
    Angela Swampillai
    Tomasz Jankowski
    Joo Hyuk Sohn
    Elena Poddubskaya
    Guzel Mukhametshina
    Sercan Aksoy
    Constanta V. Timcheva
    Tjoung-Won Park-Simon
    Antonio Antón-Torres
    Ellie John
    Katherine Baria
    Isabel Gibson
    Karen A. Gelmon
    Breast Cancer Research and Treatment, 2024, 204 : 237 - 248
  • [18] Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
    Blum, Joanne L.
    Laird, A. Douglas
    Litton, Jennifer K.
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri H.
    Lee, Kyung-Hun
    Goodwin, Annabel
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Hopkins, Julia F.
    Albacker, Lee A.
    Mina, Lida A.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1383 - 1390
  • [19] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
    Balmana, Judith
    Fasching, Peter A.
    Couch, Fergus J.
    Delaloge, Suzette
    Labidi-Galy, Intidhar
    O'Shaughnessy, Joyce
    Park, Yeon Hee
    Eisen, Andrea F.
    You, Benoit
    Bourgeois, Hughes
    Goncalves, Anthony
    Kemp, Zoe
    Swampillai, Angela
    Jankowski, Tomasz
    Sohn, Joo Hyuk
    Poddubskaya, Elena
    Mukhametshina, Guzel
    Aksoy, Sercan
    Timcheva, Constanta V.
    Park-Simon, Tjoung-Won
    Anton-Torres, Antonio
    John, Ellie
    Baria, Katherine
    Gibson, Isabel
    Gelmon, Karen A.
    Koynova, Tatyana
    Popov, Vasil
    Timcheva, Constanta
    Tomova, Antoaneta
    Eisen, Andrea
    Gelmon, Karen
    Lemieux, Julie
    Augereau, Paule
    Bazan, Fernando
    Becuwe, Celia
    Bourgeois, Hugues
    Chakiba, Camille
    Chehimi, Mohamad
    Cheneau, Caroline
    Dalenc, Florence
    de Guillebon, Eleonore
    de la Motte Rouge, Thibault
    Frenel, Jean-Sebastien
    Goncalves, Anthony
    Grenier, Julien
    Hardy-Bessard, Anne Claire
    Lamy, Regine
    Levy, Christelle
    Lortholary, Alain
    Mailliez, Audrey
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) : 237 - 248
  • [20] Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
    von Minckwitz, Gunter
    Eidtmann, Holger
    Rezai, Mahdi
    Fasching, Peter A.
    Tesch, Hans
    Eggemann, Holm
    Schrader, Iris
    Kittel, Kornelia
    Hanusch, Claus
    Kreienberg, Rolf
    Solbach, Christine
    Gerber, Bernd
    Jackisch, Christian
    Kunz, Georg
    Blohmer, Jens-Uwe
    Huober, Jens
    Hauschild, Maik
    Fehm, Tanja
    Mueller, Berit Maria
    Denkert, Carsten
    Loibl, Sibylle
    Nekljudova, Valentina
    Untch, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04): : 299 - 309
12345